Severity of COVID-19 at elevated exposure to perfluorinated alkylates.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
10
2020
accepted:
16
12
2020
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
The course of coronavirus disease 2019 (COVID-19) seems to be aggravated by air pollution, and some industrial chemicals, such as the perfluorinated alkylate substances (PFASs), are immunotoxic and may contribute to an association with disease severity. From Danish biobanks, we obtained plasma samples from 323 subjects aged 30-70 years with known SARS-CoV-2 infection. The PFAS concentrations measured at the background exposures included five PFASs known to be immunotoxic. Register data was obtained to classify disease status, other health information, and demographic variables. We used ordered logistic regression analyses to determine associations between PFAS concentrations and disease outcome. Plasma-PFAS concentrations were higher in males, in subjects with Western European background, and tended to increase with age, but were not associated with the presence of chronic disease. Of the study population, 108 (33%) had not been hospitalized, and of those hospitalized, 53 (16%) had been in intensive care or were deceased. Among the five PFASs considered, perfluorobutanoic acid (PFBA) showed an unadjusted odds ratio (OR) of 2.19 (95% confidence interval, CI, 1.39-3.46) for increasing severities of the disease. Among those hospitalized, the fully adjusted OR for getting into intensive care or expiring was 5.18 (1.29, 20.72) when based on plasma samples obtained at the time of diagnosis or up to one week before. Measures of individual exposures to immunotoxic PFASs included short-chain PFBA known to accumulate in the lungs. Elevated plasma-PFBA concentrations were associated with an increased risk of a more severe course of COVID-19. Given the low background exposure levels in this study, the role of exposure to PFASs in COVID-19 needs to be ascertained in populations with elevated exposures.
Sections du résumé
BACKGROUND
The course of coronavirus disease 2019 (COVID-19) seems to be aggravated by air pollution, and some industrial chemicals, such as the perfluorinated alkylate substances (PFASs), are immunotoxic and may contribute to an association with disease severity.
METHODS
From Danish biobanks, we obtained plasma samples from 323 subjects aged 30-70 years with known SARS-CoV-2 infection. The PFAS concentrations measured at the background exposures included five PFASs known to be immunotoxic. Register data was obtained to classify disease status, other health information, and demographic variables. We used ordered logistic regression analyses to determine associations between PFAS concentrations and disease outcome.
RESULTS
Plasma-PFAS concentrations were higher in males, in subjects with Western European background, and tended to increase with age, but were not associated with the presence of chronic disease. Of the study population, 108 (33%) had not been hospitalized, and of those hospitalized, 53 (16%) had been in intensive care or were deceased. Among the five PFASs considered, perfluorobutanoic acid (PFBA) showed an unadjusted odds ratio (OR) of 2.19 (95% confidence interval, CI, 1.39-3.46) for increasing severities of the disease. Among those hospitalized, the fully adjusted OR for getting into intensive care or expiring was 5.18 (1.29, 20.72) when based on plasma samples obtained at the time of diagnosis or up to one week before.
CONCLUSIONS
Measures of individual exposures to immunotoxic PFASs included short-chain PFBA known to accumulate in the lungs. Elevated plasma-PFBA concentrations were associated with an increased risk of a more severe course of COVID-19. Given the low background exposure levels in this study, the role of exposure to PFASs in COVID-19 needs to be ascertained in populations with elevated exposures.
Identifiants
pubmed: 33382826
doi: 10.1371/journal.pone.0244815
pii: PONE-D-20-32774
pmc: PMC7774856
doi:
Substances chimiques
Environmental Pollutants
0
Fluorocarbons
0
perfluorobutyric acid
375-22-4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244815Subventions
Organisme : NIEHS NIH HHS
ID : P42 ES027706
Pays : United States
Organisme : NIEHS NIH HHS
ID : ES027706
Pays : United States
Commentaires et corrections
Type : UpdateOf
Déclaration de conflit d'intérêts
Apart from PG having served as health expert in lawsuits on environmental contamination, which does not affect the adherence to all PLOS ONE policies, the authors have no competing interests to declare, financial or otherwise.
Références
Int J Hyg Environ Health. 2019 Jun;222(5):864-872
pubmed: 31010791
Environ Pollut. 2020 Apr;259:113857
pubmed: 31918137
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Environ Res. 2019 Feb;169:476-482
pubmed: 30530087
JAMA. 2012 Jan 25;307(4):391-7
pubmed: 22274686
Environ Res. 2020 Aug;187:109652
pubmed: 32405084
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Ann Intern Med. 2020 Nov 17;173(10):773-781
pubmed: 32783686
Int J Hyg Environ Health. 2020 Jan;223(1):34-44
pubmed: 31679856
Int J Epidemiol. 2020 Oct 1;49(5):1468-1481
pubmed: 32887982
EFSA J. 2020 Sep 17;18(9):e06223
pubmed: 32994824
J Immunotoxicol. 2013 Oct-Dec;10(4):373-9
pubmed: 23350954
Environ Health Perspect. 2018 Mar 01;126(3):037001
pubmed: 29498927
Environ Int. 2017 Jul;104:132-138
pubmed: 28392064
J Expo Sci Environ Epidemiol. 2019 Mar;29(2):148-156
pubmed: 30482935
Curr Protoc Toxicol. 2016 Feb 01;67:18.1.1-18.1.22
pubmed: 26828330
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
Environ Int. 2020 Oct 30;:106232
pubmed: 33223326
Environ Pollut. 2020 Sep;264:114732
pubmed: 32387671
J Immunotoxicol. 2016;13(2):270-3
pubmed: 26181512
Scand J Public Health. 2011 Jul;39(7 Suppl):34-7
pubmed: 21775348
Brain Behav Immun. 2020 Aug;88:44-49
pubmed: 32497776
PLoS One. 2020 May 18;15(5):e0233328
pubmed: 32421703
Clin Infect Dis. 2021 Jan 27;72(2):249-253
pubmed: 33501969
Sci Adv. 2020 Nov 4;6(45):
pubmed: 33148655
PLoS Med. 2018 Feb 13;15(2):e1002502
pubmed: 29438414
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
J Chromatogr A. 2009 Jan 16;1216(3):385-93
pubmed: 19026423
Eur J Epidemiol. 2014 Aug;29(8):541-9
pubmed: 24965263
Environ Sci Technol Lett. 2016 Oct 11;3(10):344-350
pubmed: 27752509
Sci Total Environ. 2020 Jul 20;727:138704
pubmed: 32315904
Exp Suppl. 2012;101:251-87
pubmed: 22945572
Environ Int. 2013 Sep;59:354-62
pubmed: 23892228
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
J Med Virol. 2021 Mar;93(3):1489-1495
pubmed: 32808695
Euro Surveill. 2014 Jan 09;19(1):
pubmed: 24434175
Environ Int. 2016 Nov;96:58-64
pubmed: 27608427